Earnings call transcripts

Management framed Cohort 1 as unexpectedly strong evidence that AMB033 protects both intestinal histology and symptoms, while stressing regulatory paths remain undecided.

Management framed FY26 as proof of broad-based growth, strong cash generation, and increased flexibility to invest organically or pursue acquisitions.

Management framed Delta as structurally more resilient, with pricing power and disciplined capacity offsetting doubled fuel costs and elevated operating investment.

Management framed both sports as executing well despite calendar disruption, with F1 monetization broadening and MotoGP building its commercial foundation. 13% season-to-date U.S.

Management characterized missile and GE programs as entering aggressive ramps, while lowering GE fiscal-year expectations to reflect more realistic customer production timing.

Management framed growth as broad-based and brand-led, with inventory and execution supporting momentum while investments and difficult comparisons temper the back half.

Management framed the quarter as evidence that strategic investments are translating into broad-based growth, while emphasizing uneven project timing and uncertain trade conditions.

Management framed Q2 as foundational progress in a multi-year recovery, prioritizing brand momentum, tighter execution and debt reduction over linear growth.

Management framed Q3 as a transition period, with early digital and operational improvements offset by weak retail sell-through and substantial work ahead.

Management framed Tilray as a diversified platform built to grow through integration, international cannabis and BrewDog, rather than relying on U.S. reform.

Management framed the quarter as validation of its deliberate shift toward MedTech growth, while emphasizing execution catalysts and a planned CEO transition.

Management framed Q3 as a volume-led growth milestone, while acknowledging North American beverage weakness and a margin-driven earnings reduction.